Shuai Liu^*†1, Lu Lu^*†1, Feng Pan^‡, Chunsheng Yang^*†, Jing Liang^§, Jinfeng Liu^¶, Jian Wang^#, Rong Shen^**, Fu-Ze Xin^††, Nan Zhang^*†

Oncology Research, Vol.29, No.1, pp. 25-31, 2021, DOI:10.3727/096504022X16427607626672

Abstract Fruquintinib, also called HMPL-013, was first discovered by Hutchison Whampoa Pharmaceuticals Co. Ltd., Shanghai, China, and it is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. In clinical trials, fruquintinib has demonstrated a survival benefit in metastatic colorectal cancer (mCRC) patients. The purpose of this study was to retrospectively evaluate the efficacy and toxicity of fruquintinib in real-world patients. We collected data from patients with mCRC treated with oral fruquintinib from 2018 to 2020 in six different institutions. Patients with mCRC initially received 5 mg of oral fruquintinib daily for 3 weeks. Progression-free survival… More >

ATTALLA F. EL-KOTT^1,2,*, AYMAN E. EL-KENAWY³, EMAN R. ELBEALY⁴, ALI S. ALSHEHRI¹, HEBA S. KHALIFA², MASHAEL MOHAMMED BIN-MEFERIJ⁵, EHAB E. MASSOUD^6,7,8, AMIRA M. ALRAMLAWY⁹

BIOCELL, Vol.45, No.5, pp. 1337-1353, 2021, DOI:10.32604/biocell.2021.015464 - 12 July 2021

Abstract This study examined if the anti-tumorigenesis effect of Exendin-4 in HT29 and HCT116 colorectal cancer (CRC) involves modulation of SIRT1 and Akt/GSR3K/β-catenin/NF-κB axis. HT29 and HCT116 cells were treated either with increasing levels of Exendin-4 (0.0-200 µM) or with Exendin-4 (at its IC₅₀) in the presence or absence of EX-527 (10 µM/a selective SIRT1 inhibitor) or Exendin-4 (9-39) amide (E (9-39) A) (1 µM/an Exendin-4 antagonist). In a dose-dependent manner, Exendin-4 inhibited cell survival, but enhanced levels of lactate dehydrogenase (LDH) and single-stranded DNA (ssDNA) in both HT29 and HCT116. In both cell lines and at… More >

Pierre-Guillaume Poureau^1,2,*, Estelle Dhamelincourt², Jessica Nguyen², Hélène Babey², Emmanuelle Renaud², Margaux Geier², Michèle Boisdron-Celle³, Jean-Philippe Metges²

Oncologie, Vol.23, No.2, pp. 195-202, 2021, DOI:10.32604/Oncologie.2021.015929 - 22 June 2021

Abstract Introduction: Regorafenib is a multi tyrosin-kinase inhibitor prescribed in metastatic refractory colorectal cancer treatment. Its toxicity is significant but inconstant. The metabolism of regorafenib includes oxydation via cytochrome P3A4, then glucuroconjugation. A pharmacogenetical approach of mutational status of Uridine-Diphospho-Glucuronosyltransfersase (UDP-glucuronosyl-transferase, UGT) could be a strategy to optimise the use of regorafenib. Patients and Method: This is a restrospective, unicentric study. All adult patients treated with regorafenib for a metastatic colorectal cancer in our center between 2013 and 2017 were analysed. UGT1A1 polypmorphism was previously researched in the laboratory after written informed consent. Results: Thirty-five patients… More >

CHUNJIAO LIU^1,2, QINHONG KONG^1,2, FENG PAN^1,2, SHAN JIANG^1,2, LINGJIE MENG^1,2, GAI HUANG^1,2, LIDAN LU^1,2, SANHUA LI^1,2,*, YUN LIU^1,2,3,*

BIOCELL, Vol.45, No.4, pp. 943-951, 2021, DOI:10.32604/biocell.2021.015836 - 22 April 2021

Abstract Traditional Chinese medicine (TCM) has been increasingly applied in both preventing and treating a variety of cancers in the last decades, attributing to its fewer side effects as compared with chemotherapy drugs. Hellebrigenin, a component of Chanpi from the skin of Bufo bufogargarizans Cantor or Duttaphrynus melanostictus has been reported to have an obvious anti-cancer activity on various cancers. However, the effect and mechanism of hellebrigenin on colorectal cancers were still unknown. Herein, the present study demonstrated hellebrigenin significantly reduced viability and triggered apoptosis via the intrinsic pathway in colorectal cancer cell lines HCT116 and HT29 in More >

AMAYNA ZAKARIA, SYED ABDULLAH IBN ASADUZZAMAN, ZOBAYDA NAHAR, HAFSA JARIN SNIGDHA, TASKINA MURSHED, RASHED NOOR^*

BIOCELL, Vol.45, No.3, pp. 483-487, 2021, DOI:10.32604/biocell.2021.014704 - 03 March 2021

Abstract The extent and aggression of colorectal cancer is a worldwide public health threat. Extensive research has been conducted on the pre-requisites leading to this fatal cancer. An array of genes along with their mutations and the signal transduction pathways leading to the cellular transformation into the cancerous cells have been investigated. Based on the knowledge gained so far, present review shortly discussed the role of the major genes especially those are involved in instigating abnormalities in the cellular cycles, cellular proliferation and differentiation. A simple but novel molecular scheme of the colorectal cancer development has More >

Jing Li^*†, Lian-mei Zhao^‡, Cong Zhang^‡, Meng Li^§, Bo Gao^†, Xu-hua Hu^†, Jian Cao^†, Gui-ying Wang^†

Oncology Research, Vol.28, No.1, pp. 51-63, 2020, DOI:10.3727/096504019X15619783964700

Abstract Long noncoding RNAs (lncRNAs) participate in and regulate the biological process of colorectal cancer (CRC) progression. Our previous research identified differentially expressed lncRNAs in 10 CRC tissues and 10 matched nontumor tissues by next-generation sequencing (NGS). In this study, we identified an lncRNA, FEZF1 antisense RNA 1 (FEZF1-AS1), and further explored its function and mechanism in CRC. We verified that FEZF1-AS1 is highly expressed in CRC tissues and cell lines. Through functional experiments, we found that reduced levels of FEZF1-AS1 significantly suppressed CRC cell migration, invasion, and proliferation and inhibited tumor growth in vivo. Mechanistically,… More >

Wei Wei^*1, Xiao-Dong Ma^†1, Guan-Min Jiang^‡, Bin Shi^§, Wen Zhong^¶, Chun-Lei Sun^§, Liang Zhao^*, Yan-Jiao Hou^*, Hao Wang^*

Oncology Research, Vol.28, No.4, pp. 423-438, 2020, DOI:10.3727/096504020X15877284857868

Abstract Although oxaliplatin serves as one of the first-line drugs prescribed for treating colorectal cancer (CRC), the therapeutic effect is disappointing due to drug resistance. So far, the molecular mechanisms mediating oxaliplatin resistance remain unclear. In this study, we found the chemoresistance in oxaliplatin-resistant HCT116 cells (HCT116/OXA) was mediated by the upregulation of ERCC1 expression. In addition, the acquisition of resistance induced epithelial–mesenchymal transition (EMT) as well as the Slug overexpression. On the contrary, Slug silencing reversed the EMT phenotype, decreased ERCC1 expression, and ameliorated drug resistance. Further mechanistical studies revealed the enhanced Slug expression resulted More >

Fen Liu^*†, Shaojun Liu^*, Feiyan Ai^*†, Decai Zhang^*†, Zhiming Xiao^*, Xinmin Nie^‡, Yunfeng Fu^§

Oncology Research, Vol.28, No.5, pp. 553-557, 2020, DOI:10.3727/096504020X16032056440094

Abstract Colorectal cancer (CRC) is one of the most common malignancies in the world, with a high incidence and a high mortality. However, the pathogenesis of CRC carcinogenesis is still unexplored. In this study, we investigated the role of miR-107 in the regulation of CRC cell proliferation and apoptosis. First, the expression of miR-107 was observed to be aberrantly increased in human CRC tumor tissues and cell lines when compared to the colonic control tissues and colon epithelial cells. Further study showed that the proliferative and apoptotic capacities of human CRC SW480 and LoVo cells were… More >

Andrea Lapucci^*†1, Gabriele Perrone^*†1, Antonello Di Paolo^‡§, Cristina Napoli^*†, Ida Landini^*†, Giandomenico Roviello^*†, Laura Calosi^¶, Antonio Giuseppe Naccarato^#, Alfredo Falcone^#, Daniele Bani^¶, Enrico Mini^*†§2, Stefania Nobili^*†§2,3

Oncology Research, Vol.28, No.6, pp. 631-644, 2020, DOI:10.3727/096504020X16056983169118

Abstract The benefit of adjuvant chemotherapy in the early stages of colorectal cancer (CRC) is still disappointing and the prediction of treatment outcome quite difficult. Recently, through a transcriptomic approach, we evidenced a role of PNN and KCNQ1OT1 gene expression in predicting response to fluoropyrimidine-based adjuvant chemotherapy in stage III CRC patients. Thus, the aim of this study was to validate in an independent cohort of stages II–III CRC patients our previous findings. PNN and KCNQ1OT1 mRNA expression levels were evaluated in 74 formalin-fixed paraffin-embedded tumor and matched normal mucosa samples obtained by stages II–III CRC patients treated… More >

Lili Deng^*1, Xue Yang^†1, Jun Fan^*, Yuedi Ding^*, Ying Peng^*, Dong Xu^*, Biao Huang^*‡, Zhigang Hu^†

Oncology Research, Vol.28, No.6, pp. 579-590, 2020, DOI:10.3727/096504020X15942028641011

Abstract Colorectal cancer is an aggressive malignancy for which there are limited treatment options. Oncolytic vaccinia virus is being developed as a novel strategy for cancer therapy. Arming vaccinia virus with immunostimulatory cytokines can enhance the tumor cell-specific replication and antitumor efficacy. Interleukin-24 (IL-24) is an important immune mediator, as well as a broad-spectrum tumor suppressor. We constructed a targeted vaccinia virus of Guang9 strain harboring IL-24 (VG9-IL-24) to evaluate its antitumor effects. In vitro, VG9-IL-24 induced an increased number of apoptotic cells and blocked colorectal cancer cells in the G₂ /M phase of the cell cycle. More >